Skip to main content
Erschienen in: Heart and Vessels 7/2023

25.01.2023 | Original Article

Feasibility of concomitant left atrial appendage closure and percutaneous coronary intervention in patients with acute coronary syndrome and atrial fibrillation: a randomized pilot study

verfasst von: Denis Losik, Alexander Romanov, Igor Grazhdankin, Vitaly Shabanov, Dmitry Ponomarev, Igor Mikheenko, Ivan Peregudov, Alexey Filippenko, Nikolay Bondar, Lucas Boersma, Jonathan S. Steinberg

Erschienen in: Heart and Vessels | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

The optimal approach for prevention of cardiovascular events and reduction of bleeding in patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) is still controversial. The aim of our study is to asses our single-center experience with concomitant left atrial appendage occlusion (LAAO) and percutaneous coronary intervention (PCI). 50 patients with ACS without ST elevation and history of AF were randomized after successful PCI to LAAO or conventional medical therapy. The primary endpoints were safety and length of hospitalization. The follow-up period was 30 days. The mean procedural times were 113 ± 23 min PCI + LAAO implantation and 39 ± 19 min of PCI only (p < 0.001), while mean fluoroscopy times were 18 ± 8 min and 12 ± 8 min (p < 0.001), respectively. No procedure-related complications were observed. There was no difference observed for length of hospitalization between two groups. LAAO in patients with ACS and AF undergoing PCI appears safe.

Graphical abstract

Literatur
1.
Zurück zum Zitat Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F, Document of European Society of Cardiology Working Group on Thrombosis (2010) Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a consensus document of the European society of cardiology working group on thrombosis, endorsed by the European heart rhythm association (EHRA) and the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J 31:1311–1318CrossRefPubMed Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F, Document of European Society of Cardiology Working Group on Thrombosis (2010) Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a consensus document of the European society of cardiology working group on thrombosis, endorsed by the European heart rhythm association (EHRA) and the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J 31:1311–1318CrossRefPubMed
2.
Zurück zum Zitat Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289–1367CrossRefPubMed Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289–1367CrossRefPubMed
3.
Zurück zum Zitat Ruiz-Nodar JM, Marın F, Roldan V, Valencia J, Manzano-Fernandez S, Caballero L, Hurtado JA, Sogorb F, Valdes M, Lip GY (2012) Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv 5:459–466CrossRefPubMed Ruiz-Nodar JM, Marın F, Roldan V, Valencia J, Manzano-Fernandez S, Caballero L, Hurtado JA, Sogorb F, Valdes M, Lip GY (2012) Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv 5:459–466CrossRefPubMed
4.
Zurück zum Zitat Rubboli A, Faxon D, Airaksinen K, Schlitt A, Marin F, Bhatt D, Lip G (2014) The optimal management of patients on oral anticoagulation undergoing coronary artery stenting the 10th anniversary overview. Thromb Haemost 112:1080–1087CrossRefPubMed Rubboli A, Faxon D, Airaksinen K, Schlitt A, Marin F, Bhatt D, Lip G (2014) The optimal management of patients on oral anticoagulation undergoing coronary artery stenting the 10th anniversary overview. Thromb Haemost 112:1080–1087CrossRefPubMed
5.
Zurück zum Zitat Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H, Heidbuchel H, Hendriks J, Hindricks G, Manolis A, Oldgren J, Popescu B, Schotten U, Putte B, Vardas P (2016) ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962CrossRefPubMed Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H, Heidbuchel H, Hendriks J, Hindricks G, Manolis A, Oldgren J, Popescu B, Schotten U, Putte B, Vardas P (2016) ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962CrossRefPubMed
6.
Zurück zum Zitat Holmes D, Kar S, Price M, Whisenant B, Sievert H, Doshi S, Huber K, Reddy V (2014) Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy the PREVAIL trial. J Am Coll Cardiol 64:1–12CrossRefPubMed Holmes D, Kar S, Price M, Whisenant B, Sievert H, Doshi S, Huber K, Reddy V (2014) Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy the PREVAIL trial. J Am Coll Cardiol 64:1–12CrossRefPubMed
7.
Zurück zum Zitat Holmes DR, Reddy VY, Turi ZG, Doshi S, Sievert H, Buchbinder M, Mullin C, Sick P (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised noninferiority trial. Lancet 374:534–542CrossRefPubMed Holmes DR, Reddy VY, Turi ZG, Doshi S, Sievert H, Buchbinder M, Mullin C, Sick P (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised noninferiority trial. Lancet 374:534–542CrossRefPubMed
8.
Zurück zum Zitat Romanov A, Pokushalov E, Artemenko S, Yakubov A, Stenin I, Kretov E, Krestianinov O, Grazhdankin I, Risteski D, Karaskov A, Steinberg J (2015) Does left atrial appendage closure improve the success of pulmonary vein isolation? Results of a randomized clinical trial. J Interv Card Electrophysiol 44:9–16CrossRefPubMed Romanov A, Pokushalov E, Artemenko S, Yakubov A, Stenin I, Kretov E, Krestianinov O, Grazhdankin I, Risteski D, Karaskov A, Steinberg J (2015) Does left atrial appendage closure improve the success of pulmonary vein isolation? Results of a randomized clinical trial. J Interv Card Electrophysiol 44:9–16CrossRefPubMed
9.
Zurück zum Zitat Phillips KP, Pokushalov E, Romanov A, Artemenko S, Folkeringa R, Szili-Torok T, Senatore G, Stein K, Razali O, Gordon N, Boersma L (2018) Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up. Europace 20:949–955CrossRefPubMed Phillips KP, Pokushalov E, Romanov A, Artemenko S, Folkeringa R, Szili-Torok T, Senatore G, Stein K, Razali O, Gordon N, Boersma L (2018) Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up. Europace 20:949–955CrossRefPubMed
10.
Zurück zum Zitat Chue CD, de Giovanni J, Steeds RP (2011) The role of echocardiography in percutaneous left atrial appendage occlusion. Eur J Echocardiogr 12:i3–i10CrossRefPubMed Chue CD, de Giovanni J, Steeds RP (2011) The role of echocardiography in percutaneous left atrial appendage occlusion. Eur J Echocardiogr 12:i3–i10CrossRefPubMed
11.
Zurück zum Zitat Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B (2020) EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention 15(13):1133–1180CrossRefPubMed Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B (2020) EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention 15(13):1133–1180CrossRefPubMed
12.
Zurück zum Zitat Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123(23):2736–2747CrossRefPubMed Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123(23):2736–2747CrossRefPubMed
13.
Zurück zum Zitat Cannon CP, Bhatt DL, Oldgren J, Lip GY, Ellis S, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi J, Berg J, Steg P, Hohnloser S (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524CrossRefPubMed Cannon CP, Bhatt DL, Oldgren J, Lip GY, Ellis S, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi J, Berg J, Steg P, Hohnloser S (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524CrossRefPubMed
14.
Zurück zum Zitat Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im K, Murphy SA, Magnani G, Ophuis TO, Rudah M, Parkhomenko A, Isaza D, Kamensky G, Goudev A, Montalescot G, Jensen EC, Johanson P, Braunwald E, Sabatine MS (2017) Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol 70(11):1368–1375CrossRefPubMed Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im K, Murphy SA, Magnani G, Ophuis TO, Rudah M, Parkhomenko A, Isaza D, Kamensky G, Goudev A, Montalescot G, Jensen EC, Johanson P, Braunwald E, Sabatine MS (2017) Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol 70(11):1368–1375CrossRefPubMed
15.
Zurück zum Zitat Jones DW, Minhas S, Fierro JJ, Ardeshna D, Rawal A, Cave B, Shah SP, Khouzman B (2019) From WOEST to AUGUSTUS: a review of safety and efficacy of triple versus dual antithrombotic regimens in patients with atrial fibrillation requiring percutaneous coronary intervention for acute coronary syndrome. Ann Transl Med 7:405CrossRefPubMedPubMedCentral Jones DW, Minhas S, Fierro JJ, Ardeshna D, Rawal A, Cave B, Shah SP, Khouzman B (2019) From WOEST to AUGUSTUS: a review of safety and efficacy of triple versus dual antithrombotic regimens in patients with atrial fibrillation requiring percutaneous coronary intervention for acute coronary syndrome. Ann Transl Med 7:405CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kalbacher D, Waldeyer C, Blankenberg S, Westermann D (2018) Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literature. Ann Transl Med 6(16):323CrossRefPubMedPubMedCentral Kalbacher D, Waldeyer C, Blankenberg S, Westermann D (2018) Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literature. Ann Transl Med 6(16):323CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Lopes RD, Heizer G, Aronson R, Vora A, Massaro T, Mehran R, Goodman S, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey R, Thiele H, Vinereanu D, Granger C, Alexander JH (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524CrossRefPubMed Lopes RD, Heizer G, Aronson R, Vora A, Massaro T, Mehran R, Goodman S, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey R, Thiele H, Vinereanu D, Granger C, Alexander JH (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524CrossRefPubMed
18.
Zurück zum Zitat Alhejily WA, Ohman EM (2012) Repeat revascularization after PCI: are we reinventing the wheel or refining Achilles’ heel? Circ Cardiovasc Interv 5(6):746–747CrossRefPubMed Alhejily WA, Ohman EM (2012) Repeat revascularization after PCI: are we reinventing the wheel or refining Achilles’ heel? Circ Cardiovasc Interv 5(6):746–747CrossRefPubMed
19.
Zurück zum Zitat Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pigrim T, Hong M, Kim HS, Colombo A, Steg P, Zanchin T, Palmerini T, Wallentin L, Bhatt D, Stone G, Windecker S, Steyerberg E, Valgimigli M (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034CrossRefPubMed Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pigrim T, Hong M, Kim HS, Colombo A, Steg P, Zanchin T, Palmerini T, Wallentin L, Bhatt D, Stone G, Windecker S, Steyerberg E, Valgimigli M (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034CrossRefPubMed
20.
Zurück zum Zitat Alexander JH, Lopes RD, James S, Kilaru L, He Y, Mohan P, Bhatt D, Goodman S, Verheugt F, Flather M, Huder K, Liaw D, Husted S, Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel J, Cools F, Atar D, Leiva-Pons J, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington R, Wallentin L (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708CrossRefPubMed Alexander JH, Lopes RD, James S, Kilaru L, He Y, Mohan P, Bhatt D, Goodman S, Verheugt F, Flather M, Huder K, Liaw D, Husted S, Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel J, Cools F, Atar D, Leiva-Pons J, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington R, Wallentin L (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708CrossRefPubMed
21.
Zurück zum Zitat Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson M, Kovar F, Kala P, Garcia-Hernandez A, Renfurm R, Granger C (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 32:2541–2554CrossRefPubMedPubMedCentral Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson M, Kovar F, Kala P, Garcia-Hernandez A, Renfurm R, Granger C (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 32:2541–2554CrossRefPubMedPubMedCentral
Metadaten
Titel
Feasibility of concomitant left atrial appendage closure and percutaneous coronary intervention in patients with acute coronary syndrome and atrial fibrillation: a randomized pilot study
verfasst von
Denis Losik
Alexander Romanov
Igor Grazhdankin
Vitaly Shabanov
Dmitry Ponomarev
Igor Mikheenko
Ivan Peregudov
Alexey Filippenko
Nikolay Bondar
Lucas Boersma
Jonathan S. Steinberg
Publikationsdatum
25.01.2023
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 7/2023
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-023-02236-x

Weitere Artikel der Ausgabe 7/2023

Heart and Vessels 7/2023 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.